International Journal of Mental Health and Addiction
April 1, 2024
Joseph T. Torre, Mehdi Mahammadli, Sonya C. Faber et al.
31 citations
Experts in psychiatry, clinical psychology, and psychedelic research agree that excluding people with personal or family histories of psychosis, bipolar disorder, or similar conditions from psychedelic clinical trials may be justified only when protocols offer minimal psychological support. In interviews with 12 experts, themes derived from interpretative phenomenological analysis indicated that psychedelic-, ketamine-, and MDMA-assisted psychotherapy with high levels of support are not necessarily contraindicated for all such individuals and may benefit some. Factors like specific symptoms, illness duration, severity, therapeutic alliance, trauma's role, and available supports could help predict outcomes. More research is needed to develop a safe protocol for this population.
Research Square (Research Square)
January 25, 2022
Joseph T. la Torre, Mehdi Mahammadli, Kyle T. Greenway et al.
18 citations
Experts agree that excluding people with personal or familial histories of psychotic symptoms from psychedelic-assisted psychotherapy may be justified only when protocols provide insufficient psychological support. With highly supportive therapy, such treatment is not necessarily contraindicated and may benefit individuals experiencing psychotic symptoms. Key factors for predicting outcomes include specific symptoms, illness duration, severity, therapeutic alliance quality, trauma's role, and the client's social supports.
Journal of Psychedelic Studies
July 31, 2024
Joseph T. la Torre, Jade Gallo, Mehdi Mahammadli et al.
6 citations
Most people with a history of psychotic experiences or diagnoses who used psychedelics reported personal growth, mystical-type experiences, improved insight, and feelings of love and appreciation. In an online retrospective survey of 100 such individuals, 88% said their psychedelic experience led to some degree of personal growth. However, 11% described overall negative experiences including symptom exacerbation, dysphoria, and terror, and a slightly larger portion reported mixed experiences. The findings suggest that while many individuals with psychotic histories may benefit from psychedelic experiences, a notable minority experience adverse effects, challenging assumptions that this group should be universally excluded from psychedelic research.
Journal of Psychedelic Studies
May 6, 2024
Mark Cornfield, S. Mcbride, Joseph T. la Torre et al.
6 citations
Ketamine-assisted therapy, when given to both partners during Imago Relationship Therapy, produces a wide range of effects including empathogenic, mystical, anxiolytic, and antidepressant experiences. Participants reported heightened awareness, vulnerability, and communication, along with lower defenses and novel somatic sensations. The drug's short duration, rapid onset, and cumulative effects were noted, alongside transient mild side-effects. Statistical tests indicated improved relationship satisfaction after treatment. The findings suggest ketamine may have therapeutic benefits in couples therapy under clinical supervision, but more research is needed.